-+ 0.00%
-+ 0.00%
-+ 0.00%

On July 28, Changyu Pharmaceutical Co., Ltd. announced the completion of Series D financing of RMB 250 million. This round of financing was jointly led by Yifeng Capital and Gaotejia Investment, with the participation of institutions such as Jiaxing Yuanfan and Real Capital Global. This round of financing will mainly be used for Changyu Pharmaceutical's first product, XG005, to carry out phase III acute pain clinical research in the US, and support the continuous development and globalization of the company's core product pipeline.

Zhitongcaijing·07/28/2026 05:57:02
Listen to the news
On July 28, Changyu Pharmaceutical Co., Ltd. announced the completion of Series D financing of RMB 250 million. This round of financing was jointly led by Yifeng Capital and Gaotejia Investment, with the participation of institutions such as Jiaxing Yuanfan and Real Capital Global. This round of financing will mainly be used for Changyu Pharmaceutical's first product, XG005, to carry out phase III acute pain clinical research in the US, and support the continuous development and globalization of the company's core product pipeline.